Rezdiffra (Resmetirom) is used in conjunction with diet and exercise to treat Nonalcoholic Steatohepatitis (NASH). It is the first and only FDA-approved treatment for adults with noncirrhotic NASH with moderate to advanced fibrosis. This indication is approved under accelerated approval based on improvement of NASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Rezdiffra is a
Thyroid Hormone Receptor Beta Agonist, which works by helping your body break down fat in the liver, decreasing inflammation and
scarring. The most common form of Rezdiffra is a bottle of 100mg tablets. It is also available in bottles of 60mg and 80mg tablets. There are currently no generic alternatives for Rezdiffra.